ArticleOncogene2026

CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.

Lan Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.